

AVITA MEDICAL, INC.

ARBN 641 288 155

Results for announcement to the market

| Financial Results (in thousands) | | | | June 2025 | June 2024 |
|-----------------------------------------------|------|-----|----|-----------|-----------|
| Total revenue | Up | 18% | to | \$ 36,932 | \$ 26,299 |
| Other income | Up | 42% | to | 1,693 | 1,544 |
| Net loss | Down | 30% | to | 23,779 | 34,051 |
| Total other comprehensive loss for the period | Down | 29% | to | 23,919 | 34,321 |

| Dividends | Amount per ordinary security | Franked amount per security |
|-----------------------|------------------------------|-----------------------------|
| 2025 interim dividend | Nil | Nil |
| 2024 interim dividend | Nil | Nil |

| | |
|------------------------------------------------------------------------|-----|
| Record date for determining entitlements to the 2024 interim dividends | N/A |
|------------------------------------------------------------------------|-----|

| Net Tangible Asset Backing | June 2025 | June 2024 |
|--------------------------------------------------|-------------|-----------|
| Net tangible asset backing per ordinary security | \$ (0.7999) | \$ 0.7641 |

| Other explanatory notes | | |
|--------------------------------------------------|------------------------|----------------------|
| | June 2025 | June 2024 |
| <i>Net Tangible Assets:</i> | | |
| Net assets | \$ (12,847,338) | \$ 24,310,593 |
| Right of use assets | (3,132,197) | (3,937,774) |
| Intangibles | (5,308,140) | (545,472) |
| Total net tangible assets | <u>\$ (21,287,674)</u> | <u>\$ 19,827,348</u> |
| <i>Number of ordinary shares on issue</i> | 26,613,678 | 25,949,906 |
| Net tangible asset backing per ordinary security | <u>\$ (0.7999)</u> | <u>\$ 0.7641</u> |

Additional information

Continued investment in research and development, notably an increase in intangible assets

Operating losses during the 1H of 2025 reflecting the Company's growth-stage as commercial activities scale up

An increase in working capital liabilities in support of growth

Reduction in net loss as the Company focuses on profitability and cash flow break even in 2026

Additional disclosure and further commentary on these results is contained in the attached Form 10-Q for the three months and six months ended June 30, 2025.